This startup will leverage generative AI and advanced organoid technology to predict and mitigate immunogenicity risks in antibody-based drug development. Similar to ALP Bio, it will create a platform that combines biological models (immune organoids) with AI to analyze potential immune responses to new drug candidates much earlier in the development cycle. This will help […]
